Cephalon, Inc. has announced theFDA has granteda priority review for its supplemental New Drug Application (sNDA) forNUVIGIL(R) (armodafinil) Tablets 1/8C-IV3/8, which was filed in June of thisyear. The FDA decision on approval of NUVIGIL as a treatment for improvingwakefulness in patients with excessive sleepiness associated with jet lagdisorder due to eastbound travel is expected by December 29, 2009. Therecurrently is no FDA-approved treatment for jet lag disorder.